Overview

* Vera Therapeutics ( VERA ) Q3 net loss and EPS miss analyst expectations

* Company expects BLA submission for atacicept in Q4 2025

* Vera maintains strong cash position, funding operations through potential atacicept launch

Outlook

* Company expects to submit BLA for atacicept to FDA in Q4 2025

* Vera anticipates potential U.S. launch of atacicept in 2026

* Company expects initial PIONEER trial results in Q4 2025

Result Drivers

* CLINICAL TRIAL PROGRESS - Vera is actively enrolling patients in PIONEER, dose range finding, and ORIGIN Extend studies for atacicept

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS Miss -$1.26 -$1.13

(12

Analysts

)

Q3 Net Miss -$80.29 -$75.26

Income mln mln (10

Analysts

)

Q3 Miss -$83.93 -$75.62

Operatin mln mln (11

g Income Analysts

)

Q3 $83.93

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Vera Therapeutics Inc ( VERA ) is $60.00, about 59.4% above its November 4 closing price of $24.35

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)